Quantcast

Latest Panitumumab Stories

2008-11-10 18:00:05

QIAGEN N.V. (NASDAQ: QGEN) (FRANKFURT: QIA) today announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (CRC) patients. Studies have shown that K-ras testing can better define which CRC patients will benefit from treatment with epidermal growth factor receptor (EGFR) inhibiting monoclonal antibodies, such as Amgen's Vectibix(R) (panitumumab)...

2008-09-24 12:00:00

Bristol-Myers Squibb and ImClone have presented five year data demonstrating an improved survival rate for head and neck cancer patients when receiving Erbitux and radiotherapy. Erbitux was the first targeted therapy to reach the market for this indication and looks set to maintain its market share on the basis of this positive data. The Phase III IMCL-9815 trial enrolled 424 previously untreated patients with locally or regionally advanced squamous cell carcinoma of the oropharynx, larynx...

2008-09-10 15:00:07

TrimGen Corporation, a U.S. molecular diagnostic company focused on developing advanced genetic tests, today announced the release of Mutector II(TM) KRAS kit. The new assay screens all 12 mutations in codons 12 and 13 of the KRAS gene with 1% detection sensitivity, which has significant implications for patients with colon cancer receiving chemotherapy. There are 12 possible mutations in codons 12 and 13 of the KRAS gene that may affect chemotherapy. Sequencing is the most common method...

2008-08-04 21:00:07

MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The trial was conducted at 10 centres across...

2008-07-02 12:01:11

Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer. In colorectal cancers, EGF-receptors transmit a series of signals through a complex path of intracellular proteins. These signals ultimately instruct the cancer cell to undergo a transcription process leading to cancer progression. Anti-EGF-receptor therapies such as panitumumab and cetuximab work by...

2008-07-01 06:00:12

ALISO VIEJO, Calif., July 1 /PRNewswire-FirstCall/ -- Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced its new offering, KRAS, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer (CRC). The importance of KRAS testing was recently reported at this year's ASCO meeting in Chicago and is...

2008-06-30 12:03:15

Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan. Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human...

2008-06-26 18:02:59

Amgen (NASDAQ: AMGN) today announced updated results from the "STEPP" (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer (mCRC) patients receiving epidermal growth factor receptor (EGFr) therapy. The analysis found that preemptive treatment reduced the incidence rate of grade 2 and greater skin toxicities by over 50 percent without...

2008-06-24 09:03:24

IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix)...

2008-06-20 12:00:46

Merck KGaA has submitted an application to the European Medicines Agency to broaden the use of the targeted therapy Erbitux to include first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The submitted label would extend the use of Erbitux for treatment of patients with recurrent or metastatic squamous cell cancer of the head and neck in combination with platinum-based chemotherapy. The submission is supported by data from the...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'